Stock comparison
Artivion
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AORT
Artivion
Market cap
$1.09B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AORT | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 75B | IDXX |
| Benjamin Graham | 63D | 80A | IDXX |
| Philip Fisher | 48D | 75B | IDXX |
| Peter Lynch | 32F | 71B | IDXX |
| Joel Greenblatt | 41D | 83C | IDXX |
| Charlie Munger | 43D | 87A | IDXX |
| Terry Smith | 36D | 84A | IDXX |
Side-by-side metrics
| Metric | AORT | IDXX |
|---|---|---|
| Market cap | $1.09B | $44.12B |
| P/E (TTM) | 93.6x | 39.0x |
| EV/EBIT | 48.9x | 31.6x |
| ROIC (TTM) | 3.0% | 40.66% |
| Gross margin | 62.94% | 62.05% |
| Net margin | 2.55% | 24.63% |
| Revenue CAGR 5y | 10.24% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.6x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AORT leads on
- Revenue CAGR 5y10.24%vs 7.56%+26%
- Debt / Equity0.6xvs 0.7x+17%
IDXX leads on
- Market cap$44.12Bvs $1.09B+98%
- ROIC (TTM)40.66%vs 3.0%+93%
- Net margin24.63%vs 2.55%+90%
- P/E (TTM)39.0xvs 93.6x+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.